AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02957565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment Questionnaires
Description: After viewing first video, participant completes assessment questionnaire to evaluate their opinion of the physicians behavior. These questionnaires should take about 5 minutes to complete.~After viewing second video, participant completes the same 3 assessment questionnaires. Participant also completes 2 additional questionnaires asking which physician participant would prefer as a primary physician and the satisfaction with health information technology use in their care.
Study NCT01610271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air Barrier System
Description: ABS is a device that emits a stream of purified air over the surgical site creating a barrier that prevents the intrusion of bacteria.
Study NCT06025851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-human CCL24 monoclonal antibody (CM-101)
Description: Intravenous Infusion of Anti-human CCL24 monoclonal antibody (CM-101)
Study NCT06025851 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study NCT03625206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive bias modification training
Description: These training sessions aim to modify a selective attention bias towards threat and a tendency to interpret ambiguous situations in threatening ways
Study NCT03625206 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control training
Description: These exercises are matched to the task demands of the modules of cognitive bias modification training
Study NCT03359239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg administered by IV infusion every 3 weeks (21 \[+/-2\] days) for up to 12 months in the adjuvant setting and up to 24 months in the metastatic setting.
Study NCT03359239 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGV001
Description: PGV001: up to ten total doses of PGV001with helper peptides. The product is prepared within the ISMMS . The product consists of two independent preparations of patient specific long peptides mixed with poly-ICLC.~A dose of PGV001 consists of the following:~Up to ten synthetic peptides - 100μg (0.01 mL, 10 mg/mL) per peptide. One tetanus helper peptide - 100μg (0.01 mL, 10 mg/mL)
Study NCT03359239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: 1.4 mg (0.7 mL, 2 mg/mL)
Study NCT03359239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: 0.19 mL
Study NCT02376855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eConsult
Description: An electronic consultation or eConsult is a secure message consult that allows specialists to provide advice on cases without seeing a patient face to face. They contain a reason for consult, any relevant tests, procedures or reports. The responsibility lies with the primary care provider to act, or not act on the advice as they deem fit.
Study NCT04491708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercises
Description: The participants attended two half-hour Pilates exercise classes twice a week, for one month, to familiarize themselves with the exercises and to learn the 5 Pilates' principles. After the learning period, two experimental sessions were performed: a Mat Pilates session and a Reformer apparatus Pilates session. The order of each session was randomized and drawn beforehand. Each experimental session lasted about one and a half hours and the interval between the sessions was 48 hours. Participants were asked to not perform any exercise and to refrain from food or fluids except water eight hours prior to each experimental session. Prior to the start of the experimental sessions, participants received a standard breakfast of 321 kcal that was 76% (61 g) carbohydrate, 8% (6,7 g) protein, 16% (5,9) fat, provided by the study researchers. All sessions were conducted at the same time in the morning, and the room temperature (22°C) and humidity (40-50%) were controlled during the whole session.
Study NCT01919476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bagel
Study NCT03219879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-administered continuation therapy
Description: The intervention includes eight therapy sessions of approx. 50 minutes duration delivered over the telephone by trained psychotherapists over a time period of six months. The intervention is grounded in the principles of psychological continuation therapy and relapse prevention, and includes strategies such as transferring helpful elements of acute-phase cognitive-behavioral therapy (CBT) for depression to daily life. T-CT is offered in addition to usual care.
Study NCT01919476 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bagel
Study NCT01919476 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cream Cheese
Study NCT03219879 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care without any study-related intervention
Study NCT01721070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil NanoTab (SUF NT) 15 mcg
Description: Period 1: One dose of SUF NT 15 mcg administered sublingually
Study NCT01919476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond Butter
Study NCT02973152 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thyroplasty
Description: This medialisation/augmentation technique is a static technique, performed under local anaesthesia that aims to improve the positioning of the paralysed vocal fold. It uses a silastic implant readily available in different sizes according to size of larynx and gender of the patient. The correct size can be determined intraoperatively by using a measuring device while listening and visualising the larynx with flexible fiberoptic scope simultaneously.
Study NCT02973152 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reinnervation
Description: For laryngeal reinnervation, ansa cervicalis to recurrent laryngeal nerve repair technique will be used. In this technique, the functioning ansa cervicalis nerve that overlies the internal jugular vein and the distal stump of injured recurrent laryngeal nerve (RLN) will be identified and anastomosed without tension (Crumley RL. Teflon versus thyroplasty versus nerve transfer: a comparison. The Annals of otology, rhinology, and laryngology. 1990;99(10 Pt 1):759-63).
Study NCT00100893 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IH636 grape seed proanthocyanidin extract
Description: Dose escalation as follows: 50 mg/day, 300 mg/day, 1000 mg/day, 2000 mg/day, 2800 mg/day, 4000 mg/day, 4800 mg/day and 6000 mg/day in separate patient groups for each dosage
Study NCT01721070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg, sufentanil NanoTab (SUF NT) 15 mcg
Description: Period 2: Ketoconazole 400 mg administered daily for three days, SUF NT 15 mcg co-administered sublingually on the third day
Study NCT04878640 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: patients with morbid obesity and gall bladder stone underwent concomitant laparoscopic cholecystectomy in the same setting during laparoscopic sleeve gastrectomy
Description: patients with morbid obesity and gall bladder stone underwent concomitant laparoscopic cholecystectomy in the same setting during laparoscopic sleeve gastrectomy
Study NCT02679651 — intervention group
Intervention type: OTHER
Intervention: Ultrasound of the foot
Description: An ultrasound will be used to determine the thickness of the fat pad
Study NCT04878640 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: patients with morbid obesity and gall bladder stone underwent laparoscopic sleeve gastrectomy without concomitant laparoscopic cholecystectomy
Description: patients with morbid obesity and gall bladder stone underwent laparoscopic sleeve gastrectomy without concomitant laparoscopic cholecystectomy
Study NCT02678988 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI-1000 G2
Description: The device will contain TCZ (180 milligrams per milliliter \[mg/mL\]) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS and assembled in the AI (AI-1000 G2).
Study NCT03657862 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: application of 38% silver diamine fluoride solution
Description: SDF solution was painted onto the surface of the carious lesion of the tooth
Study NCT03657862 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: application of a placebo (tonic water)
Description: tonic water was painted onto the surface of the carious lesion of the tooth
Study NCT02207673 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tailoring of the resection based on biomarker in aEcoG during epilepsy surgery
Study NCT02207673 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tailoring of the resection based on biomarker in aEcoG during epilepsy surgery
Study NCT03866187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd155-hIi-HBV low dose formulation
Description: Subjects in group A1 receive one dose of ChAd155-hIi-HBV low dose formulation at Day 1, by intramuscular injection in the deltoid of the non-dominant arm.
Study NCT03866187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd155-hIi-HBV high dose formulation
Description: Subjects in groups B1 and B3 receive one dose of ChAd155-hIi-HBV high dose formulation at Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the non-dominant arm.~Subjects in groups C1 and C2 receive one dose of ChAd155-hIi-HBV high dose formulation at Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the dominant arm.
Study NCT03866187 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd155-hIi-HBV high dose formulation
Description: Subjects in groups B1 and B3 receive one dose of ChAd155-hIi-HBV high dose formulation at Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the non-dominant arm.~Subjects in groups C1 and C2 receive one dose of ChAd155-hIi-HBV high dose formulation at Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the dominant arm.
Study NCT01978015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: travoprost and timolol maleate fixed combination
Description: travoprost 0.004% and timolol maleate 0,5%, 1 eye drop at 8p.m. for 6 months
Study NCT01978015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: latanoprost and maleate timolol fixed combination
Description: Latanoprost 0.005% and timolol maleate 0,5%, 1 eye drop at 8 p.m for 6 months
Study NCT03866187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBc-HBs/AS01B-4 low dose formulation
Description: Subjects in group A1 receive two doses of HBc-HBs/AS01B-4 low dose formulation, one at Day 113 and one at Day 169 and subjects in group A2 receive four doses of the low dose formulation, one dose each at Days 1, 57, 113 and 169, by intramuscular injection in the deltoid of the non-dominant arm.
Study NCT03866187 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HBc-HBs/AS01B-4 low dose formulation
Description: Subjects in group A1 receive two doses of HBc-HBs/AS01B-4 low dose formulation, one at Day 113 and one at Day 169 and subjects in group A2 receive four doses of the low dose formulation, one dose each at Days 1, 57, 113 and 169, by intramuscular injection in the deltoid of the non-dominant arm.
Study NCT03866187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBc-HBs/AS01B-4 high dose formulation
Description: Subjects in group B1 receive two doses of HBc-HBs/AS01B-4 high dose formulation, one at Day 113 and one at 169; subjects in group B2 receive four doses, one dose each at Days 1, 57, 113 and 169; subjects in group C1 receive four co-administered doses at Days 1, 57, 113 and 169 and subjects in group C2 receive two co-administered doses at Days 113 and 169, by intramuscular injection in the deltoid of the non-dominant arm.
Study NCT03866187 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HBc-HBs/AS01B-4 high dose formulation
Description: Subjects in group B1 receive two doses of HBc-HBs/AS01B-4 high dose formulation, one at Day 113 and one at 169; subjects in group B2 receive four doses, one dose each at Days 1, 57, 113 and 169; subjects in group C1 receive four co-administered doses at Days 1, 57, 113 and 169 and subjects in group C2 receive two co-administered doses at Days 113 and 169, by intramuscular injection in the deltoid of the non-dominant arm.
Study NCT03866187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-HBV low dose formulation
Description: Subjects in group A1 receive one dose of MVA-HBV low dose formulation at Day 57, by intramuscular injection in the deltoid of the non-dominant arm.
Study NCT03866187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-HBV high dose formulation
Description: Subjects in groups B1 and B3 receive one dose of MVA-HBV high dose formulation at Day 57 and Day 169 respectively, by intramuscular injection in the deltoid of the non-dominant arm.~Subjects in group C1 receive three co-administered doses of the vaccine at Days 57, 113 and 169 and subjects in group C2 receive one co-administered dose of the vaccine at Day 169, by intramuscular injection in the deltoid of the dominant arm.
Study NCT03866187 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA-HBV high dose formulation
Description: Subjects in groups B1 and B3 receive one dose of MVA-HBV high dose formulation at Day 57 and Day 169 respectively, by intramuscular injection in the deltoid of the non-dominant arm.~Subjects in group C1 receive three co-administered doses of the vaccine at Days 57, 113 and 169 and subjects in group C2 receive one co-administered dose of the vaccine at Day 169, by intramuscular injection in the deltoid of the dominant arm.
Study NCT02679651 — intervention group
Intervention type: OTHER
Intervention: Pedobarograph Measurements
Description: This non-invasive device measures the force and pressure of the foot while standing and walking.
Study NCT03866187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in group A3 receive four doses of placebo, one each at Days 1, 57, 113 and 169 and subjects in group B3 receive two doses of placebo one each at Days 1 and 57, by intramuscular injection in the deltoid of the non-dominant arm. Subjects in group C2 receive 2 co-administered doses of placebo at Days 1 and 57, by intramuscular injection in the deltoid of the dominant and non-dominant arm.
Study NCT03866187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects in group A3 receive four doses of placebo, one each at Days 1, 57, 113 and 169 and subjects in group B3 receive two doses of placebo one each at Days 1 and 57, by intramuscular injection in the deltoid of the non-dominant arm. Subjects in group C2 receive 2 co-administered doses of placebo at Days 1 and 57, by intramuscular injection in the deltoid of the dominant and non-dominant arm.
Study NCT02679651 — intervention group
Intervention type: OTHER
Intervention: Manchester Foot Pain and Disability Index
Description: This is a patient completed questionnaire that assesses level of function from the past month specific to foot pain.
Study NCT02806895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JZP-110
Study NCT02806895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02730338 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High intensity aerobic and resistance training
Study NCT02730338 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial support
Study NCT02730338 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychosocial support
Study NCT02678988 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFS-NSD
Description: The device will contain TCZ (180 mg/mL) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS-NSD.
Study NCT02678988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive two single doses of 162 mg tocilizumab SC on Day 1 (Period 1) and Day 43 (Period 2), with a washout period of 6 weeks between the periods.
Study NCT02204007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D imaging & surrogate bone model
Description: 3D imaging \& surrogate bone model to assist with acetabular shell placement. Different that standard of care preoperative imaging
Study NCT03052907 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: BSPAN
Description: 1. Identify readiness assessment criteria (RAC) essential in determining a rural county's capacity to support comprehensive mammography and appropriate follow-up services.~2. Using the RAC, we will determine which of the five BSPAN1 counties have capacity to manage and sustain the Outreach \& Health Promotion and Delivery \& Navigation components of the program (High Capacity), and which have the capacity to manage and sustain only the Outreach \& Health Promotion component (Medium Capacity).~3. Expand BSPAN to 12 new rural and underserved counties according to RAC score and evaluate each county's ability to implement program components and increase comprehensive mammography and appropriate follow-up.
Study NCT00735696 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: 10 milligrams per kilogram (mg/kg), intravenous (IV) infusion, on Day 1 of each 21-day cycle.
Study NCT00735696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200 milligrams per meter squared (mg/m\^2), administered intravenously (IV) following the ramucirumab infusion, on day 1 of each 21-day cycle, for up to six cycles.
Study NCT01520454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: IV saline at 0.83 mL/kg/hr for six hours
Study NCT00735696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered after paclitaxel, as an intravenous infusion (IV), over 30 minutes on day 1 of each 21-day cycle, for up to six cycles. The dose to be administered is calculated based on the participant's actual body weight at time of treatment and the area under the curve (AUC) dosing. The target AUC for carboplatin treatment is AUC=6.
Study NCT02511860 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Burdock
Description: Subjects will consume burdock daily and will undergo laboratory tests to determine the effect of burdock, if any, on organ function.
Study NCT02511860 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Methylcellulose (inert) tablet taken as placebo
Study NCT01684280 — intervention group
Intervention type: GENETIC
Intervention: gender
Description: Paired samples of abdominal subcutaneous and intrabdominal omental adipose tissue were obtained from men and women who underwent bariatric surgery.
Study NCT01552330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine and Pyronaridine-artesunate
Description: Subject will receive primaquine (PQ) then receive pyronaridine-artesunate (PA)after 1 week washout period and receive PQ together with PA for the third regimen after 8 weeks washout period~Primaquine:~- Dosage: 2 tablets~and~Pyronaridine-Artesunate:~- Dosage: 3 tablets
Study NCT01552330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine and Pyronaridine-Artesunate
Description: Subject will receive primaquine (PQ) then receive PQ together dihydroartemisinin-piperaquine (DHA-PQP) after 1 week washout period and receive DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~- Dosage: 2 tablets~and~Pyronaridine-Artesunate:~- Dosage: 3 tablets
Study NCT03023189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: At randomisation : loading dose of 1g of intravenous tranexamic acid for 10 min, immediately followed by an intravenous infusion of 3g of TA over 24h.~Total dose : 4 g of TA
Study NCT03023189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At randomisation : loading dose of 10 mL of intravenous isotonic saline for 10 min, immediately followed by an intravenous infusion of 30 mL of isotonic saline over 24h Total dose : 40 mL of Placebo
Study NCT00324896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eszopiclone
Description: eszopiclone
Study NCT00324896 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo administered at night
Study NCT01003951 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture treatments will be given at the Integrative Medicine Outpatient Center, if needed in particular cases, at the MSKCC Breast Center. Each treatment is 30-40 minutes in duration. Each patient will receive two acupuncture treatments each week for four consecutive weeks.~Before and after each treatment, the circumference of the patient's upper arm, and forearm will be measured in both the affected and unaffected arms. The greater difference between affected and unaffected arms (either the forearm or the upper arm) for each patient will be used for outcome assessment. Photographs of the patient's affected and unaffected arms before and after each treatment will be taken to provide visual documentation of status. The patient's face will not appear in the photographs. Blood draws will be performed from the unaffected arm in serum collection tubes and will be performed within 1 week of starting acupuncture and within 1 week of completion of the 4 week protocol.
Study NCT04192032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preferred Juul pod flavor (5% nicotine)
Description: Preferred Juul pod flavor (5% nicotine)